超越对接:USP7抑制剂优化的多层计算管道。

IF 3.6 4区 医学 Q2 CHEMISTRY, MEDICINAL
ChemMedChem Pub Date : 2025-04-27 DOI:10.1002/cmdc.202500210
Serdar Durdagi, Ehsan Sayyah, Muhammet Eren Ulug, Serdar Durdağı
{"title":"超越对接:USP7抑制剂优化的多层计算管道。","authors":"Serdar Durdagi, Ehsan Sayyah, Muhammet Eren Ulug, Serdar Durdağı","doi":"10.1002/cmdc.202500210","DOIUrl":null,"url":null,"abstract":"<p><p>Ubiquitin-specific protease 7 (USP7) is a key deubiquitinating enzyme involved in tumor suppression, DNA repair, and epigenetic regulation. Given its critical role in cancer progression, USP7 has emerged as an attractive therapeutic target. In this study, we employed a multi-tier computational approach, integrating ligand-based virtual screening, molecular docking, MD simulations, MM/GBSA binding free energy calculations, binary QSAR modeling, and steered MD simulations to identify and optimize novel USP7 inhibitors. Using SwissSimilarity-based ligand screening, we selected structurally related analogs of previously identified and validated hit compounds by our research group and performed grid-based docking simulations, prioritizing molecules with high binding affinity (docking scores < -8.0 kcal/mol). The top-ranked candidates were refined through long-term MD simulations and MM/GBSA free energy calculations to assess their structural stability and interaction patterns with key USP7 residues. Binary QSAR analysis further evaluated the anticancer potential of these compounds, filtering those with high predicted therapeutic activity (normalized therapeutic activity value > 0.5). Furthermore, to investigate selectivity of the potent compounds, we performed cross-docking against multiple USP family members. Finally, sMD simulations provided insights into the mechanical stability of ligand-protein interactions. The identified candidates hold promise for further in vitro studies, advancing USP7-targeted therapies for cancer treatment.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202500210"},"PeriodicalIF":3.6000,"publicationDate":"2025-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Beyond Docking: A Multi-Tier Computational Pipeline for USP7 Inhibitor Optimization.\",\"authors\":\"Serdar Durdagi, Ehsan Sayyah, Muhammet Eren Ulug, Serdar Durdağı\",\"doi\":\"10.1002/cmdc.202500210\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Ubiquitin-specific protease 7 (USP7) is a key deubiquitinating enzyme involved in tumor suppression, DNA repair, and epigenetic regulation. Given its critical role in cancer progression, USP7 has emerged as an attractive therapeutic target. In this study, we employed a multi-tier computational approach, integrating ligand-based virtual screening, molecular docking, MD simulations, MM/GBSA binding free energy calculations, binary QSAR modeling, and steered MD simulations to identify and optimize novel USP7 inhibitors. Using SwissSimilarity-based ligand screening, we selected structurally related analogs of previously identified and validated hit compounds by our research group and performed grid-based docking simulations, prioritizing molecules with high binding affinity (docking scores < -8.0 kcal/mol). The top-ranked candidates were refined through long-term MD simulations and MM/GBSA free energy calculations to assess their structural stability and interaction patterns with key USP7 residues. Binary QSAR analysis further evaluated the anticancer potential of these compounds, filtering those with high predicted therapeutic activity (normalized therapeutic activity value > 0.5). Furthermore, to investigate selectivity of the potent compounds, we performed cross-docking against multiple USP family members. Finally, sMD simulations provided insights into the mechanical stability of ligand-protein interactions. The identified candidates hold promise for further in vitro studies, advancing USP7-targeted therapies for cancer treatment.</p>\",\"PeriodicalId\":147,\"journal\":{\"name\":\"ChemMedChem\",\"volume\":\" \",\"pages\":\"e202500210\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-04-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ChemMedChem\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/cmdc.202500210\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cmdc.202500210","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

泛素特异性蛋白酶7 (USP7)是一个关键的去泛素化酶,参与肿瘤抑制、DNA修复和表观遗传调控。鉴于其在癌症进展中的关键作用,USP7已成为一个有吸引力的治疗靶点。在这项研究中,我们采用了多层计算方法,整合了基于配体的虚拟筛选、分子对接、MD模拟、MM/GBSA结合自由能计算、二元QSAR建模,并指导MD模拟来识别和优化新的USP7抑制剂。通过基于swisssimilarity的配体筛选,我们选择了先前研究小组鉴定和验证的命中化合物的结构相关类似物,并进行了基于网格的对接模拟,优先考虑高结合亲和力(对接分数< -8.0 kcal/mol)的分子。通过长期的MD模拟和MM/GBSA自由能计算来评估它们的结构稳定性和与关键USP7残基的相互作用模式。二元QSAR分析进一步评估了这些化合物的抗癌潜力,过滤了那些具有高预测治疗活性的化合物(标准化治疗活性值> 0.5)。此外,为了研究有效化合物的选择性,我们对多个USP家族成员进行了交叉对接。最后,sMD模拟提供了对配体-蛋白质相互作用的机械稳定性的见解。确定的候选药物有望进一步进行体外研究,推进usp7靶向治疗癌症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Beyond Docking: A Multi-Tier Computational Pipeline for USP7 Inhibitor Optimization.

Ubiquitin-specific protease 7 (USP7) is a key deubiquitinating enzyme involved in tumor suppression, DNA repair, and epigenetic regulation. Given its critical role in cancer progression, USP7 has emerged as an attractive therapeutic target. In this study, we employed a multi-tier computational approach, integrating ligand-based virtual screening, molecular docking, MD simulations, MM/GBSA binding free energy calculations, binary QSAR modeling, and steered MD simulations to identify and optimize novel USP7 inhibitors. Using SwissSimilarity-based ligand screening, we selected structurally related analogs of previously identified and validated hit compounds by our research group and performed grid-based docking simulations, prioritizing molecules with high binding affinity (docking scores < -8.0 kcal/mol). The top-ranked candidates were refined through long-term MD simulations and MM/GBSA free energy calculations to assess their structural stability and interaction patterns with key USP7 residues. Binary QSAR analysis further evaluated the anticancer potential of these compounds, filtering those with high predicted therapeutic activity (normalized therapeutic activity value > 0.5). Furthermore, to investigate selectivity of the potent compounds, we performed cross-docking against multiple USP family members. Finally, sMD simulations provided insights into the mechanical stability of ligand-protein interactions. The identified candidates hold promise for further in vitro studies, advancing USP7-targeted therapies for cancer treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ChemMedChem
ChemMedChem 医学-药学
CiteScore
6.70
自引率
2.90%
发文量
280
审稿时长
1 months
期刊介绍: Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信